Free Trial
NASDAQ:CTKB

Cytek Biosciences (CTKB) Stock Price, News & Analysis

Cytek Biosciences logo
$7.08 -0.07 (-0.98%)
(As of 02:43 PM ET)

About Cytek Biosciences Stock (NASDAQ:CTKB)

Key Stats

Today's Range
$7.00
$7.23
50-Day Range
$4.69
$7.40
52-Week Range
$4.66
$9.87
Volume
440,905 shs
Average Volume
695,079 shs
Market Capitalization
$931.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.17
Consensus Rating
Buy

Company Overview

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Cytek Biosciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
70th Percentile Overall Score

CTKB MarketRank™: 

Cytek Biosciences scored higher than 70% of companies evaluated by MarketBeat, and ranked 452nd out of 977 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cytek Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cytek Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cytek Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Cytek Biosciences are expected to grow in the coming year, from ($0.11) to $0.03 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cytek Biosciences is -88.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cytek Biosciences is -88.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cytek Biosciences has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Cytek Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    3.59% of the float of Cytek Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytek Biosciences has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Cytek Biosciences has recently decreased by 6.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cytek Biosciences does not currently pay a dividend.

  • Dividend Growth

    Cytek Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.59% of the float of Cytek Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytek Biosciences has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Cytek Biosciences has recently decreased by 6.04%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cytek Biosciences has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Cytek Biosciences this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for CTKB on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Cytek Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cytek Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.60% of the stock of Cytek Biosciences is held by insiders.

  • Percentage Held by Institutions

    69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cytek Biosciences' insider trading history.
Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CTKB Stock News Headlines

Cytek Biosciences introduces ESP Detection Option for Cytek Aurora
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Cytek Biosciences Reports Third Quarter 2024 Financial Results
See More Headlines

CTKB Stock Analysis - Frequently Asked Questions

Cytek Biosciences' stock was trading at $9.12 on January 1st, 2024. Since then, CTKB shares have decreased by 22.0% and is now trading at $7.11.
View the best growth stocks for 2024 here
.

Cytek Biosciences, Inc. (NASDAQ:CTKB) issued its quarterly earnings data on Tuesday, November, 5th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.02) by $0.03. The business had revenue of $51.50 million for the quarter, compared to analyst estimates of $50.63 million. Cytek Biosciences had a negative net margin of 5.05% and a negative trailing twelve-month return on equity of 2.58%.

Cytek Biosciences (CTKB) raised $248 million in an initial public offering on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share.

Cytek Biosciences' top institutional shareholders include Brown Capital Management LLC (7.22%), Charles Schwab Investment Management Inc. (0.78%), Connor Clark & Lunn Investment Management Ltd. (0.47%) and Principal Financial Group Inc. (0.38%). Insiders that own company stock include Ming Yan, Wenbin Jiang, Patrik Jeanmonod, Jack Ball and Ra Capital Management, LP.
View institutional ownership trends
.

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytek Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY) and Humana (HUM).

Company Calendar

Last Earnings
11/05/2024
Today
11/12/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/12/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:CTKB
Fax
N/A
Employees
500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.17
High Stock Price Target
$10.00
Low Stock Price Target
$8.50
Potential Upside/Downside
+29.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-12,150,000.00
Pretax Margin
-5.92%

Debt

Sales & Book Value

Annual Sales
$193.01 million
Cash Flow
$0.03 per share
Book Value
$2.93 per share

Miscellaneous

Free Float
118,881,000
Market Cap
$933.72 million
Optionable
Optionable
Beta
1.32
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:CTKB) was last updated on 11/12/2024 by MarketBeat.com Staff
From Our Partners